Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration

AI-generated analysis

πŸ’° Kymera Therapeutics posted a first-quarter 2026 loss of 71 cents per share, narrowing from a loss of 82 cents in the year-ago quarter.

πŸ“ˆ Quarterly revenues reached $34.37 million, representing a 55.5% year-over-year increase that significantly exceeded analyst estimates.

🀝 All revenue recognized in Q1 was driven exclusively by the collaboration with Gilead Sciences, where upfront payments were fully recognized.

πŸ’Έ Operating expenses rose as the company increased investment in its clinical pipeline and discovery engine to $98.2 million.

πŸ’° General and administrative costs increased 25.1% to $20.4 million due to higher legal fees and personnel costs associated with being a public company.

πŸ’΅ Kymera ended the quarter with $1.55 billion in cash, providing an operating runway expected to last into 2029.

🀝 Gilead exercised its option to exclusively license KT-200, triggering a $45 million milestone payment expected in the second quarter.

πŸ’° The partnership agreement with Gilead includes eligibility for approximately $700 million of additional milestone payments.

πŸ”¬ KT-621 remains the company's lead program, an oral STAT6 degrader advancing in two parallel Phase IIb trials for atopic dermatitis and asthma.

βš•οΈ The FDA granted Fast Track designation to KT-621 for moderate-to-severe eosinophilic asthma in addition to its prior designation for atopic dermatitis.

🧬 Kymera is progressing KT-579, an oral IRF5 degrader for autoimmune diseases, which recently received IND clearance for a first-in-human Phase I study.

πŸ”¬ KT-485/SAR447971, a partner program with Sanofi targeting IRAK4, completed IND-enabling studies and is expected to enter clinical trials in 2026.

πŸ“ˆ Year-to-date, KYMR shares have gained 5.3% compared to the industry's 1.1% decline.

πŸ† The company reiterated that its cash resources are sufficient to fund ongoing Phase IIb execution and pipeline expansion for later-stage development.

⭐ Zacks analyst ranks Kymera Therapeutics with a #3 (Hold) rating.

Bullish Signals
  • Kymera Therapeutics posted Q1 earnings that topped estimates with a loss of 71 cents per share, which is narrower than the consensus estimate of 89 cents.
  • Quarterly revenues surged to $34.37 million, representing a 55.5% year-over-year increase and surpassing the Zacks Consensus Estimate of $11 million.
  • The company's partnership with Gilead Sciences (GILD) was a primary driver of revenue, resulting in a fully recognized upfront payment that sets the stage for milestone-driven variability.
  • Management received a decision from Gilead to exercise its option to exclusively license KT-200, triggering an expected $45 million milestone payment receivable in Q2 and eligibility for roughly $700 million in additional milestones.
  • Kymera exited the quarter with $1.55 billion in cash, cash equivalents, and investments, providing a supported operating runway into 2029.
  • The FDA granted Fast Track designation to KT-621 for moderate-to-severe eosinophilic asthma, complementing its existing Fast Track status in atopic dermatitis.
  • Year to date, KYMR shares gained 5.3% against the industry's 1.1% decline, outperforming peers despite market headwinds.
  • KT-621 is advancing in two parallel Phase IIb trials in dermatology and respiratory indications with enrollment expected to be completed in 2026.
Risk Factors
  • Kymera Therapeutics reported a net loss of 71 cents per share in Q1 2026, which, while better than the consensus estimate of an 89 cent loss, still reflects negative earnings.
  • R&D expenses surged to $98.2 million, a 22.3% year-over-year increase driven by scaling clinical pipeline investments and growth in the R&D organization.
  • General and administrative expenses rose 25.1% to $20.4 million due to increased personnel, facility costs, and legal fees associated with being a public company.
  • The upfront payment from the Gilead partnership has been fully recognized, meaning future collaboration revenue will be entirely dependent on milestone payments rather than recurring income.
  • All Q1 collaboration revenues came solely from Gilead (GILD), creating concentration risk as no other significant partner revenue streams were recognized in the quarter.
  • The company currently holds a Zacks Rank #3 (Hold), which is a neutral-to-negative rating compared to competitors like Castle Biosciences that hold a #1 Strong Buy rank.
  • Clinical trial timelines for lead assets KT-621 and KT-579 extend into 2026 and 2027, delaying potential returns on the heavy R&D spend before commercialization.
  • Kymera's cash runway extends to 2029, which is a long-term commitment that exposes the company to valuation pressure if clinical success rates fall short of expectations.
Full Analysis
Kymera Therapeutics (KYMR) reported first-quarter 2026 earnings that surpassed analyst expectations, driven largely by significant revenue growth from its collaboration with Gilead Sciences (GILD). The company posted a loss of 71 cents per share compared to a Zacks Consensus Estimate of a loss of 89 cents, marking an improvement over the year-ago quarter's loss of 82 cents. Quarterly revenues reached $34.37 million, representing a 55.5% year-over-year increase and exceeding the consensus estimate of $11 million. Notably, all collaboration revenue recognized in the quarter came from Gilead; the company also secured a key development by having Gilead exercise its option to exclusively license KT-200, a first-in-class oral CDK2 molecular glue degrader. This exercise triggers a $45 million milestone payment expected in the second quarter and sets eligibility for approximately $700 million in additional milestone payments. Despite the revenue gains, operating expenses increased as the company scaled its clinical execution and discovery engine. Research and development expenses rose 22.3% year over year to $98.2 million, reflecting higher spending on the STAT6 program, platform technologies, and organizational growth. General and administrative expenses also climbed 25.1% to $20.4 million due to increased legal fees, professional services, and personnel costs associated with being a public company. Nevertheless, Kymera ended the quarter with $1.55 billion in cash, cash equivalents, and investments, providing an operating runway expected to extend into 2029. The financial performance is underpinned by substantial progress across its pipeline, particularly with KT-621, an investigational once-daily oral STAT6 degrader for type II inflammatory diseases. The company is advancing KT-621 in two parallel phase IIb trials: the BROADEN2 study for atopic dermatitis and the BREADTH study for moderate-to-severe eosinophilic asthma. Regulatory momentum has been bolstered by FDA Fast Track designations for KT-621 in both conditions. Additionally, the company is progressing KT-579, an IRF5 degrader for autoimmune diseases, which recently received IND clearance and began dosing in a first-in-human phase I study, while its partner program with Sanofi, KT-485/SAR447971, is expected to enter clinical trials in 2026. Market reaction to the results has been positive, with KYMR shares gaining 5.3% year-to-date against the industry's 1.1% decline. Management emphasized that their cash resources are sufficient to fund ongoing Phase IIb execution for KT-621, advance KT-579 into early proof-of-concept planning, and support continued pipeline expansion. The company reiterated that the investment thesis centers on pipeline execution in targeted protein degradation, led by KT-621, which is currently in phase II trials for dermatology and respiratory indications with data anticipated by mid-to-late 2027.